Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nurix Therapeutics Inc (NQ: NRIX )

21.86 -0.23 (-1.02%)
Streaming Delayed Price Updated: 11:26 AM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nurix Therapeutics Inc

< Previous 1 2 3 Next >
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
Analyst Ratings for Nurix Therapeutics
Within the last quarter, Nurix Therapeutics (NASDAQ:NRIX) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022
Upgrades 
Via Benzinga
10 Biggest Price Target Changes For Friday
Keybanc boosted Broadcom Inc. (NASDAQ: AVGO) price target from $720 to $780. Broadcom shares rose 0.1% to $551.44 in pre-market trading. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a... 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
Nurix Therapeutics Doses First Patient in Phase 1a/1b Study of NX-5948 For B-cell malignancies
Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that the first patient has been dosed in the Phase 1a/1b study to evaluate orally available small molecule NX-5948, in patients with relapsed B-cell... 
Via Benzinga
Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest
Clay Siegall and the board agreed it would be in investors' best interest if he resigned. 
Via Investor's Business Daily
Nurix Therapeutics' BTK Programs Show Encouraging Preclinical Action In Blood Cancer, Solid Tumors
Nurix Therapeutics Inc (NASDAQ: NRIX) announced the  
Via Benzinga
61 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Nurix Therapeutics: Q4 Earnings Insights
Nurix Therapeutics (NASDAQ:NRIX) reported its Q4 earnings results on Thursday, January 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and... 
Via Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current 
Via Talk Markets
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company... 
Via Benzinga
Why Nurix Therapeutics Stock Soared More Than 21% Wednesday
The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers. 
Via The Motley Fool
64 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
Why Did SVB Leerink Beef Up Target Price For Nurix Therapeutics?
SVB Leerink raised the price target on Nurix Therapeutics Inc (NASDAQ: NRIX) to $64 from $50, with an Outperform rating, seeing an upside of almost 92%. Analyst... 
Via Benzinga
Nurix Shares Gain On Encouraging Early Data From Blood Cancer Trial
Nurix Therapeutics Inc (NASDAQ: NRIX) announced initial data from Phase 1a trial of NX-2127 in relapsed or refractory B cell malignancies. Initial data from the... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
Return on Capital Employed Insights for Nurix Therapeutics
After pulling data from Benzinga Pro it seems like during Q2, Nurix Therapeutics (NASDAQ:NRIX) brought in sales totaling $7.09 million. However, earnings decreased 7.72%,... 
Via Benzinga
Return on Capital Employed Insights for Nurix Therapeutics
After pulling data from Benzinga Pro it seems like during Q2, Nurix Therapeutics (NASDAQ:NRIX) brought in sales totaling $7.09 million. However, earnings decreased 7.72%,... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.